SynthesisCell biology and toxicology2025
Copper-cysteamine nanoparticles in cancer treatment: a systematic review.
Synthesis in Cell biology and toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Copper-cysteamine nanoparticles (Cu-Cy NPs) represent an innovative approach for cancer therapy due to their unique ability to be activated by multiple physical and chemical stimuli. This review systematically evaluates studies investigating Cu-Cy NPs in combination with chemical agents and diverse energy sources, including X-rays, UV light, microwaves, and ultrasound. A comprehensive literature search in PubMed, Scopus, and Web of Science up to August 2025 identified 18 relevant studies encompassing both in vitro and in vivo experiments. Across these studies, Cu-Cy NPs consistently suppressed tumor growth and triggered cancer cell death by generating reactive oxygen species (ROS) and enhanced therapeutic effects when combined with co-treatments such as disulfiram, potassium iodide, and other adjunct therapies. The multi-modal activation of Cu-Cy NPs, along with their ability to enhance existing therapeutic approaches, demonstrates a novel strategy in cancer treatment that integrates chemical and physical mechanisms for maximal efficacy. These findings underscore the nanoparticles' potential to transform current oncology strategies, offering targeted, versatile, and personalized therapeutic options. Continued investigation is essential to fully elucidate their mechanisms, optimize treatment protocols, and translate these promising preclinical results into safe and effective clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.